Monte Rosa Therapeutics Inc.

04/28/2025 | Press release | Distributed by Public on 04/28/2025 05:24

AACR 2025 – Selective Targeting of CDK2 Using Molecular Glue Degraders for the Treatment of HR-Positive/HER2-Negative Breast Cancer